Remicade
Remicade is a pharmaceutical drug with 16 clinical trials. Historical success rate of 93.3%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
10
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
93.3%
14 of 15 finished
6.7%
1 ended early
0
trials recruiting
16
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis
CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
Clinical Trials (16)
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis
CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action
Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease
Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis
Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy
Growth Factor Concentration to Predict an Ankylosing Spondylitis Patient's Response to Infliximab (Study P04041)(COMPLETED)
Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)
All 16 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 16